Alopecia is a condition in which hairs are lost from some or all areas of the body. In fact, alopecia areata is also known as spot baldness for this reason. Most commonly, patients have bald spots on their scalps about the size of a coin.
There are three (3) well-known types of Alopecia
- Alopecia areata patchy — The most common form, with one or more coin-sized hairless patches on the scalp or other areas of the body
- Alopecia totalis — Total loss of the hair on the scalp
- Alopecia universalis — Complete loss of hair on the scalp, face and body1
What Is Alopecia Characterized As?
Alopecia Areata is a common autoimmune skin disease which causes hair loss on the scalp, face, and sometimes on other areas of the body.1 It is a common, clinically heterogenous, immune-mediated, non-scarring hair loss disorder.3 It occurs when your immune system mistakenly attacks hair follicles, which is where hair growth begins.2
Alopecia areata is known as a “polygenic disease.” This means that, unlike a single-gene disease, both parents must contribute a number of specific genes in order for a child to develop it.1
What are Alopecia Symptoms?
Some of the common symptoms of Alopecia Areata are as follows:
- Small, round (or oval) patches of hair loss on the scalp, beard area of the face or other areas of the body with hair
- Hair loss and regrowth at the same time in different areas of the body
- Significant hair loss in a very short period of time
- Hair loss that’s mostly on one side of the scalp, instead of both sides
- “Exclamation point” hairs that are narrow at the base/next to the scalp
- “Stippling” or “Pitting” (rows of tiny dents) on the fingernails 1
What is the Prevalence of Alopecia?
Alopecia Areata affects as many as 6.8 million people in the U.S. with 147 million people worldwide.1 Alopecia Areata tends to occur most often in adults 30 to 60 years of age.6 Ithas a lifetime risk of 2.1%.1
Hospital-based studies from across the world have estimated the incidence of AA to be between 0.57% and 3.8%, as detailed in Table 1.
Table 1: Incidence of alopecia areata globally
Abbreviation: n/a, not applicable.
People of all ages, both sexes and all ethnic groups can develop Alopecia Areata. It often first appears during childhood and can be different for everyone who has it, and there is no way to predict the pattern of hair loss and regrowth that will be experienced or how severe or long lasting it will be.1
In Canada, the annual years of healthy life lost per 100,000 people from Alopecia Areata has increased by 10.7% since 1990, an average of 0.5% a year.4
What are Available Treatments of Alopecia?
Treatment of alopecia areata is dependent on age of patient as well as the extent and duration of scalp involvement. Treatments include steroids, topical immunotherapy, topical minoxidil, anthralin, and immunosuppressants. Each case must be dealt with on a customized individual basis.5
It was reported in 2013-14 that there were no FDA (Food and Drug Administration)-approved
treatments for alopecia areata (AA).5 However, following kinds of therapies are utilized.
Localized Therapy For Alopecia
- Intralesional corticosteroids
- Topical corticosteroids
- Topical immunotherapy
Systemic Therapy For Alopecia
- Psychosocial support
Clinical Trials in Alopecia?
Alopecia has been a widely studied indication. There are consistent efforts ongoing to find effective treatment for this disorder. A search on clinicaltrials.gov reveals a total of 207 studies worldwide.
While, most of the trials were centered in North America, Canada got a small number of trials in alopecia, as reported in clinicaltrials.gov. Most of these trials were centered in British Columbia and Ontario provinces.
Clinical Trial Feasibility in Alopecia – Current Trial
A clinical trial feasibility in Alopecia is being performed on Credevo.6
This clinical trial will be conducted in adults patients with Alopecia.
Sites and region
Total 10 sites from Canada are required in this clinical trial.
Of course, Investigators and sites with capability and expertise in dermatology are being explored for this clinical trial.
Submit your response
If you’re an investigator or site team from Canada, working in dermatology and interested in such clinical trials, please visit Credevo. Here are the direct links for you
Free sign up for investigators on Credevo: It’s required to view clinical trial details and submit your response. This is a one-time activity and you can use same account for feasibility submissions later.
Free sign up for clinical study coordinators and site personnel on Credevo: If you’re a clinical study coordinator or a site personnel supporting your investigator and find such clinical trial interesting, sign up on Credevo and participate in feasibility on behalf of your investigator.
- Shapiro J (2013). “Current treatment of alopecia areata.”. J Investig Dermatol Symp Proc (Review). 16 (1): S42–4. PMID 24326551. doi:10.1038/jidsymp.2013.14
- Clinical trial feasibility in Alopecia on Credevo (https://credevo.com/myzone/submit_feasibility?project_id=20)